News | January 01, 2007

Traumatic Stress Sets Stage for Heart Disease

Reuters reports that a study of military veterans suffering from post-traumatic stress disorder showed that more severe their anxiety, the greater their risk of heart disease. Adding to the long-recognized connection between stress and heart disease, researchers at the Harvard School of Public Health in Boston said that relationship existed among nearly 2,000 Boston-area veterans.

Post-traumatic stress disorder, or PTSD, once dismissed as "combat fatigue," can also afflict people who experience traumatic events. It is characterized by anxiety, re-experiences of the event and avoidance of stimuli related to the experience, the Reuters article explained.

The study demonstrated that each step up in symptom severity increased the risk of a heart attack by 26 percent, the report said.

"This pattern of effects suggests that individuals with higher levels of (post-traumatic stress disorder) symptoms are not simply prone to reporting higher levels of chest pain or other physical symptoms but may well be at higher risk for developing coronary heart disease," wrote study author Laura Kubzansky in the Archives of General Psychiatry.


Related Content

News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
Subscribe Now